Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Moderna | Applied Digital | Vistra | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | narrow The 10-K states that "the majority of our facilities operate as “merchant” facilities without long-term power sales agreements" and that Vistra is "not guaranteed any rate of return on our capital investments". Against that, the scarcity is real: six NRC-licensed nuclear units totalling 6,448 MW, licences running 2036-2053, inside a 43,641 MW fleet, plus 20-year PPAs with AWS (1,200 MW) and Meta (2,609 MW). The 2025 gas additions - Lotus (2,600 MW, closed October 2025) and pending Cogentrix (5,500 MW) - extend the merchant gas side, not the nuclear scarcity. Only the 433 MW of uprates extends the moat asset. |
| Moat type | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | intangibles ip The intangibles are non-replicable regulatory assets rather than patents: six nuclear licences (Comanche Peak 2050/2053, Perry 2046, Davis-Besse 2037, Beaver Valley 2036/2047), fuel "contracted to support all our refueling needs through 2030", section 45U credits "recognizing the value of existing carbon-free nuclear power", and TXU Energy, sold "for over 20 years" and "registered and protected by trademark law". Read 45U as a floor, not moat strength: the 2025 credit was $220m against $545m in 2024, and it "provides increasing levels of support as unit revenues decline". Efficient scale does not apply. |
| Leadership | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | co leader Vistra describes itself as "one of the largest producers of power in deregulated markets in the U.S." with over 230 TWh generated, "one of the largest competitive power generators in the U.S. as measured by MWh of generation capacity", "one of the largest electricity generators in the U.S.", and "one of the largest competitive residential retail electricity providers". That hedged phrasing appears four times and is the strongest claim the filing makes. The 10-K names no competitor and assigns no rank, so co-leader is the ceiling the disclosure supports. |
| Pricing power | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | weak Vistra is a merchant price taker. Price formation rests on "the highest variable cost unit that clears the market", prices are "unpredictable and may fluctuate substantially", hedging markets have "limited liquidity after two to three years", and competing retailers "may offer different products, lower electricity prices and other incentives". ERCOT's $2,000/MWh figure is the low system-wide offer cap, applied conditionally when the peaker net margin exceeds three times CONE or under the PUCT Emergency Pricing Program, not a standing cap. PJM has "announced that it would propose" extending its capacity cap to 2028-29 and 2029-30, subject to FERC approval. |
| Summary | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | Vistra's moat is one scarce asset wrapped in a commodity business. Six NRC-licensed nuclear units - 6,448 MW, licences running 2036-2053 - sit inside a 43,641 MW fleet that the 10-K says operates in the majority as "merchant" facilities with no long-term power sales agreements and no guaranteed rate of return. That block cannot be rebuilt by a rival, and is now partly de-risked by 20-year PPAs with AWS (1,200 MW from Comanche Peak) and Meta (2,609 MW from the PJM plants) plus section 45U credits. Everything else - 26,989 MW of gas, 8,743 MW of coal, the 5m-customer retail book - competes on price in markets Vistra does not set, against entrants the filing says keep building "despite relatively low power prices". The 2025 growth was gas M&A (Lotus, pending Cogentrix), which widens the commodity-exposed side. Narrow, for a specific reason: the moat is 15% of the fleet. |
| Chain position | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | Merchant IPP: sells energy, capacity and ancillary services into ISO/RTO spot and short-term wholesale markets (ERCOT, PJM, ISO-NE, NYISO, CAISO, MISO) and resells to ~5m retail customers. Emerging role as long-term nuclear offtake supplier to hyperscalers (AWS, Meta). Not a price setter at any link. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |